Recordati S.p.a. · MIL:REC
Recordati — UBS 2007 Global Generic and Specialty Pharmaceuticals Conference
11 slides from Recordati's conference presentation, May 8, 2007
Slide 1: Growing internationally
UBS 2007 Global Generic and Specialty Pharmaceuticals Conference, New York, 8 May 2007 Growing internationally
Slide 2: Company profile
Company profile ¾ A fully integrated pharmaceutical company listed on the Italian Stock Exchange since 1984 ¾ Original research focused on cardiovascular and urological fields ¾ A European company - marketing operations in all the main countries (France, Germany, Italy, Spain, UK) and more recently,
Slide 3: Pharmaceutical revenue by geographical area
Pharmaceutical revenue by geographical area UK Ireland Spain Germany 2% 0.2% International licensees Portugal 7% 4% 20% 8% 22% % of pharmaceutical revenue 37% France Zanidip® (lercanidipine) 31% Italy Elopram® /Entact® 7% (citalopram/escitalopram) Peptazol® (pantoprazole) 3% Licensed Tora-Dol® (keto
Slide 4: ZANIDIP (lercanidipine) % share of CCB market
ZANIDIP® (lercanidipine) ¾ Latest generation calcium-channel blocker. Lercanidipine as a % of all Lipophilic dihydropyridine. calcium channel blockers ¾ Natural once a day. Potent, long-lasting Bubble size represents $ market value of CCB’s vasodilatory activity. Highly vasoselective with gradual on
Slide 5: R&D pipeline
R&D pipeline NAME ORIGINATOR INDICATION PHASE Zanipress®/Zanitek® Recordati Hypertension (lercanidipine+enalapril) Launched in the RMS (Germany) rupatadine Uriach Rhinitis, allergic, seasonal / perennial urticaria Approved fentanyl patch Lavipharm Moderate to severe chronic pain Filed in the RMS (UK
Slide 6: Zanitek/Zanipress (lercanidipine+enalapril) launched in Germany (RMS)
Zanitek®/Zanipress® (lercanidipine+enalapril) launched in Germany (RMS) ¾ Fixed combinations will play a significant role in the future hypertension market ¾ New aggressive targets for blood pressure control. Combination of drugs needed for most patients ¾ Increased patient compliance ¾ Recent large
Slide 7: First quarter 2007 operational highlights
First quarter 2007 operational highlights ¾ Record quarterly results ¾ Revenue € 163.4 million, EBIT € 37.1 million, net income € 23.5 million ¾ International sales grow by 8.2% ¾ Lercanidipine sales up 7.3% ¾ Direct marketing of Zanidip® in Ireland by Recordati Ireland ¾ Meda to co-market lercanidi
Slide 8: First quarter 2007 results
First quarter 2007 results (million euro) 1Q 2007 1Q 2006 Change Revenue 163.4 161.7 1.1 % Gross Profit 109.0 108.4 0.6 % as % of revenue 66.7% 67.0% SG&A Expenses 58.8 62.5 (5.8) % as % of revenue 36.0% 38.7% R&D Expenses 13.0 11.7 as % of revenue 7.9% 7.3% 10.5 % Operating Income 37.1 34.5 7.6% as
Slide 9: Net financial position
Net financial position (million euro) 31 Mar 2007 31 Dec 2006 Change Cash and short term financial 155.2 145.0 10.2 investments Bank overdrafts (14.4) (14.6) 0.2 Loans – due within one year (12.0) (20.4) 8.4 Loans – due after one year (86.4) (87.6) 1.3 NET FINANCIAL POSITION 42.5 22.4 20.1 8
Slide 10: Targets, strategy and assumptions
Targets, strategy and assumptions (million euro) 2007 2006 Change (million euro) 2010 REVENUE 650 576.2 13% 1,000 REVENUE OPERATING INCOME 132 120.3 10% OPERATING INCOME >200 NET INCOME 83 74.0 12% NET INCOME >120 • Reinforce current geographic coverage in Germany • Profitability of existing busines
Slide 11: Safe harbour and company profile
Safe harbour and company profile Statements contained in this presentation, other than historical facts, are “forward-looking statements” (as such term is defined in the Private Securities Litigation Reform Act of 1995). These statements are based on currently available information, on current best
Recordati — UBS 2007 Global Generic and Specialty Pharmaceuticals Conference on 6ix